齐鲁制药牵手国自然基金委 9900万元联合基金破解医药基础研究瓶颈

Core Insights - The signing ceremony of the National Natural Science Foundation's Private Enterprise Innovation Development Joint Fund marks a historic moment for China's biopharmaceutical basic research and original innovation, with Qilu Pharmaceutical committing to invest 90 million yuan over three years [1][6] - This initiative aims to enhance the integration of basic and applied research, addressing significant challenges in disease prevention and treatment [1][6] Group 1: Investment and Collaboration - Qilu Pharmaceutical will invest 30 million yuan annually, totaling 90 million yuan, while the National Natural Science Foundation will match this with 3 million yuan per year, amounting to 9 million yuan over three years [6] - The collaboration will establish a mechanism where enterprises propose research topics, and the scientific community responds, focusing on five core areas: immune disorders, abnormal cell proliferation, gene mutation and expression regulation, metabolic disorders, and neurological diseases [6] Group 2: Significance of the Joint Fund - The Joint Fund aims to leverage the guiding role of the National Natural Science Foundation to encourage private enterprises to increase their investment in basic research, attracting national research strengths to address critical scientific issues [6][5] - This initiative is expected to stimulate innovation vitality in private enterprises and contribute to the implementation of national science and technology innovation strategies [6][5] Group 3: Industry Context and Challenges - China's basic research funding accounts for about 6% of total R&D expenditure, significantly lower than the approximately 15% in major developed countries, indicating a need for increased corporate investment in basic research [7] - Despite the introduction of innovative drugs, the pharmaceutical industry in China still faces challenges such as product homogeneity and a lack of transformative mechanisms and targets [7] Group 4: Qilu Pharmaceutical's Position - Qilu Pharmaceutical is a leading domestic pharmaceutical company, with over 320 products listed and a strong competitive position in the industry, leading in consistency evaluations and national procurement bids [7][8] - The company has established a robust international R&D system supported by six major platforms, employing over 5,000 dedicated R&D personnel, with R&D investment accounting for 12% of sales revenue [8]